90Y-FAPI-46治疗导致3例孤立性纤维性肿瘤患者近乎完全的代谢反应

Helena Lanzafame, Christoph E. Heilig, Eva Wardelmann, Mélanie Desaulniers, Kim Magaly Pabst, Ilektra Antonia Mavroeidi, Ina Pretzell, Pedro Fragoso Costa, Micheal Nader, Stephan Leyser, Martin Schuler, Sebastian Bauer, Jens Thomas Siveke, Leila Kamkar, Simon Kreutzfeldt, Stefan Fröhling, Sebastian Mühl, Ken Herrmann, Wolfgang Peter Fendler, Rainer Hamacher
{"title":"90Y-FAPI-46治疗导致3例孤立性纤维性肿瘤患者近乎完全的代谢反应","authors":"Helena Lanzafame, Christoph E. Heilig, Eva Wardelmann, Mélanie Desaulniers, Kim Magaly Pabst, Ilektra Antonia Mavroeidi, Ina Pretzell, Pedro Fragoso Costa, Micheal Nader, Stephan Leyser, Martin Schuler, Sebastian Bauer, Jens Thomas Siveke, Leila Kamkar, Simon Kreutzfeldt, Stefan Fröhling, Sebastian Mühl, Ken Herrmann, Wolfgang Peter Fendler, Rainer Hamacher","doi":"10.2967/jnumed.125.269572","DOIUrl":null,"url":null,"abstract":"<p>Solitary fibrous tumor (SFT) is a rare soft-tissue sarcoma with limited treatment options, especially in advanced or metastatic cases. Fibroblast activation protein α (FAPα) is overexpressed in certain sarcomas, including SFTs, making it a promising target for diagnostics and radiopharmaceutical therapy (RPT). We present the cases of 3 patients with metastatic SFTs who, after exhausting standard treatments, underwent molecular profiling and showed elevated FAPα expression. <strong>Methods:</strong> Messenger RNA and protein expression of FAPα were examined in biopsy samples from 3 patients participating in the Molecularly Aided Stratification for Tumor Eradication Research program, a multicenter observational study focused on biology-driven stratification of adults with advanced cancer. Messenger RNA expression levels were quantified as transcripts per million, with RNA extraction, sequencing, and data processing performed using established protocols. Protein expression was assessed and stained with FAPα immunohistochemistry using a recombinant anti-FAPα antibody. Following the recommendation of the molecular tumor board, these patients received <sup>90</sup>Y-labeled fibroblast activation protein inhibitor (FAPI)-46 RPT because of the high uptake observed in <sup>68</sup>Ga-FAPI-46 PET/CT scans. <strong>Results:</strong> <sup>90</sup>Y-FAPI-46 RPT led to substantial clinical benefits, including metabolic resolution and symptom relief, with disease control confirmed using RECIST and PERCIST. Treatment was well-tolerated, with only minor adverse events observed. <strong>Conclusion:</strong> Our findings underscore the utility of FAPα screening as a predictive biomarker and the potential of FAP-targeted RPT as a viable treatment for advanced SFT.</p>","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"20 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"90Y-FAPI-46 Theranostics Leads to Near-Complete Metabolic Response in 3 Patients with Solitary Fibrous Tumors\",\"authors\":\"Helena Lanzafame, Christoph E. Heilig, Eva Wardelmann, Mélanie Desaulniers, Kim Magaly Pabst, Ilektra Antonia Mavroeidi, Ina Pretzell, Pedro Fragoso Costa, Micheal Nader, Stephan Leyser, Martin Schuler, Sebastian Bauer, Jens Thomas Siveke, Leila Kamkar, Simon Kreutzfeldt, Stefan Fröhling, Sebastian Mühl, Ken Herrmann, Wolfgang Peter Fendler, Rainer Hamacher\",\"doi\":\"10.2967/jnumed.125.269572\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Solitary fibrous tumor (SFT) is a rare soft-tissue sarcoma with limited treatment options, especially in advanced or metastatic cases. Fibroblast activation protein α (FAPα) is overexpressed in certain sarcomas, including SFTs, making it a promising target for diagnostics and radiopharmaceutical therapy (RPT). We present the cases of 3 patients with metastatic SFTs who, after exhausting standard treatments, underwent molecular profiling and showed elevated FAPα expression. <strong>Methods:</strong> Messenger RNA and protein expression of FAPα were examined in biopsy samples from 3 patients participating in the Molecularly Aided Stratification for Tumor Eradication Research program, a multicenter observational study focused on biology-driven stratification of adults with advanced cancer. Messenger RNA expression levels were quantified as transcripts per million, with RNA extraction, sequencing, and data processing performed using established protocols. Protein expression was assessed and stained with FAPα immunohistochemistry using a recombinant anti-FAPα antibody. Following the recommendation of the molecular tumor board, these patients received <sup>90</sup>Y-labeled fibroblast activation protein inhibitor (FAPI)-46 RPT because of the high uptake observed in <sup>68</sup>Ga-FAPI-46 PET/CT scans. <strong>Results:</strong> <sup>90</sup>Y-FAPI-46 RPT led to substantial clinical benefits, including metabolic resolution and symptom relief, with disease control confirmed using RECIST and PERCIST. Treatment was well-tolerated, with only minor adverse events observed. <strong>Conclusion:</strong> Our findings underscore the utility of FAPα screening as a predictive biomarker and the potential of FAP-targeted RPT as a viable treatment for advanced SFT.</p>\",\"PeriodicalId\":22820,\"journal\":{\"name\":\"The Journal of Nuclear Medicine\",\"volume\":\"20 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-07-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Journal of Nuclear Medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2967/jnumed.125.269572\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Journal of Nuclear Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2967/jnumed.125.269572","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

孤立性纤维性肿瘤(SFT)是一种罕见的软组织肉瘤,治疗方案有限,特别是在晚期或转移病例中。成纤维细胞活化蛋白α (FAPα)在包括SFTs在内的某些肉瘤中过表达,使其成为诊断和放射药物治疗(RPT)的一个有希望的靶点。我们报告了3例转移性SFTs患者,在经过标准治疗后,进行了分子分析,发现FAPα表达升高。方法:参与分子辅助分层用于肿瘤根除研究项目的3例患者的活检样本中检测了信使RNA和FAPα的蛋白表达,该项目是一项多中心观察性研究,重点研究成人晚期癌症的生物学驱动分层。信使RNA表达水平被量化为每百万转录本,RNA提取、测序和数据处理使用既定的协议进行。用重组抗FAPα抗体免疫组化法检测蛋白表达并染色。根据分子肿瘤委员会的建议,这些患者接受了90y标记的成纤维细胞活化蛋白抑制剂(FAPI)-46 RPT,因为在68Ga-FAPI-46 PET/CT扫描中观察到高摄取。结果:90Y-FAPI-46 RPT带来了实质性的临床益处,包括代谢缓解和症状缓解,并通过RECIST和PERCIST确认疾病控制。治疗耐受性良好,仅观察到轻微的不良事件。结论:我们的研究结果强调了FAPα筛选作为一种预测性生物标志物的效用,以及fap靶向RPT作为晚期SFT的可行治疗方法的潜力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
90Y-FAPI-46 Theranostics Leads to Near-Complete Metabolic Response in 3 Patients with Solitary Fibrous Tumors

Solitary fibrous tumor (SFT) is a rare soft-tissue sarcoma with limited treatment options, especially in advanced or metastatic cases. Fibroblast activation protein α (FAPα) is overexpressed in certain sarcomas, including SFTs, making it a promising target for diagnostics and radiopharmaceutical therapy (RPT). We present the cases of 3 patients with metastatic SFTs who, after exhausting standard treatments, underwent molecular profiling and showed elevated FAPα expression. Methods: Messenger RNA and protein expression of FAPα were examined in biopsy samples from 3 patients participating in the Molecularly Aided Stratification for Tumor Eradication Research program, a multicenter observational study focused on biology-driven stratification of adults with advanced cancer. Messenger RNA expression levels were quantified as transcripts per million, with RNA extraction, sequencing, and data processing performed using established protocols. Protein expression was assessed and stained with FAPα immunohistochemistry using a recombinant anti-FAPα antibody. Following the recommendation of the molecular tumor board, these patients received 90Y-labeled fibroblast activation protein inhibitor (FAPI)-46 RPT because of the high uptake observed in 68Ga-FAPI-46 PET/CT scans. Results: 90Y-FAPI-46 RPT led to substantial clinical benefits, including metabolic resolution and symptom relief, with disease control confirmed using RECIST and PERCIST. Treatment was well-tolerated, with only minor adverse events observed. Conclusion: Our findings underscore the utility of FAPα screening as a predictive biomarker and the potential of FAP-targeted RPT as a viable treatment for advanced SFT.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信